ReviewJournal of clinical medicine2024
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Proteome Remodelling inJournal of fungi (Basel, Switzerland) · 2026Article
- Morphotype-specific susceptibility toMicrobiology spectrum · 2026Article
- Beyond intrinsic resistance: novel insights into the emergence and management of resistance acquired in Candida auris upon antifungal exposure.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Kombucha-Mediated Silver Nanoparticles with Fungicidal Activity Against WHO-PriorityCurrent issues in molecular biology · 2026Article
- Article
- Review
- Clinical Impact ofJournal of Korean medical science · 2026Article
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- Breaking the Chain of Infection: A Systematic Review of Environmental Decontamination ofJournal of fungi (Basel, Switzerland) · 2026Review
- Development of a Loop-Mediated Isothermal Amplification (LAMP) for the screening of Candida auris.PloS one · 2026Article
- A targeted drug-repurposing strategy identifies TavaboroleFrontiers in microbiology · 2026Article
- Article
- Fungus Among Us: An 8-Year Retrospective Study of Fungal Infections at a Tertiary-Care Hospital in Bucharest, Romania.Pathogens (Basel, Switzerland) · 2025Article
- Minimum Inhibitory Concentrations of Anidulafungin as a Potential Predictor of Biocide Susceptibility of Clade 1 Candidozyma (Candida) auris Isolates.MicrobiologyOpen · 2025Article
- Candidemia in a General Hospital in Kuwait: Epidemiology, Species Distribution, Risk Factors, and Antifungal Susceptibility Patterns over a 10-Year Period (2015-2024).Journal of fungi (Basel, Switzerland) · 2025Article
- Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.Scientific reports · 2025Article
- Trends in Antifungal Resistance AmongJournal of fungi (Basel, Switzerland) · 2025Article
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- Analysis of Candidozyma auris - an emerging threat in intensive care units.GMS hygiene and infection control · 2025Article
- Hospital-acquiredJournal of family & community medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida auris (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.